Janux Therapeutics

Congrats to our CEO, David Campbell, who has been recognized by STAT as one of the top ‘science’ CEOs of 2024! This highlights David’s leadership and Janux Therapeutics’ unwavering mission to redefine cancer treatment. Guided by our commitment to scientific integrity, innovation, and putting patients first, we are working tirelessly to bring transformative therapies to those in need. See the full list here: https://lnkd.in/gfzf5GQZ #JANX #TCellEngagers #cancer #oncology #immunotherapy #immunomodulator #immunooncology #clinicaltrial #mCRPC #prostatecancer

For Lina Ma, PhD, DABT, urgency leads to opportunity and drives impact. It's a value we share here at Janux, where we are lucky to have Lina serving as director of pharmacology. She recently reflected on what urgency means for her and her colleagues. As she notes, urgency has a purpose, not only to meet a timeline or overcome temporary obstacles, but also to deliver safe and effective therapeutics that every cancer patient deserves. Every moment counts in the fight against cancer. Let’s make them matter. #Culture #LeadByExample #CoreValues #LifeatJanux #Urgency

Janux has successfully closed its underwritten public offering, raising a remarkable $402.5 million in total gross proceeds, which includes the full exercise of underwriters' options to purchase additional shares. This milestone is a strong testament to the belief in Janux's pioneering approach to advancing next-generation T cell engager immunotherapies. Congratulations to the Janux team on this major achievement! 🎉 Learn more about this milestone here: https://lnkd.in/eyJTVKSQ #JANX #TCellEngagers #cancer #oncology #immunotherapy #immunomodulator #immunooncology #clinicaltrial #mCRPC #prostatecancer

Another #Movember comes to an end, and we are grateful to the #JanuxMoBros and those that supported us in raising awareness for prostate cancer and men’s health. For Janux, this event helps inspire us as we work to develop meaningful new immunotherapies to improve outcomes in #mCRPC. Our mustaches might fade, but the message remains: early detection and support can make a world of difference. Let’s keep the conversation going!    #ProstateCancerAwareness #Movember2024 #prostatecancer #menshealth #mentalhealthmatters #GoJanux 

We’re pleased to announce doses selected for Phase 1b expansion trials supported by encouraging efficacy and safety profile observed in Phase 1a dose escalation for JANX007 in #mCRPC. Join our virtual investor event today at 4:30pm ET. Read the release for more details and to register for the event: https://lnkd.in/g39hJMwH #JANX #TCellEngagers #cancer #oncology #immunotherapy #immunomodulator #immunooncology #clinicaltrial #mCRPC #prostatecancer

🍂 The Janux team came together for a wonderful potluck filled with delicious food, laughter, and gratitude. It was a heartwarming reminder of the values that drive us every day: collaboration in how we support one another, integrity in all that we do, and a shared sense of urgency to make a difference in the lives of patients. As we celebrate together, we're thankful for our dedicated team and the progress we've made this year. Here's to continuing our commitment to transforming lives through innovation and teamwork! #TeamJanux #Gratitude

We will be hosting a virtual event on Monday, December 2nd at 4:30pm ET to discuss updated clinical data in Phase 1a dose escalation for JANX007 in mCRPC and doses selected for Phase 1b expansion studies. A live Q&A session will follow the formal presentation. For details on how to register for the event, see the press release: https://lnkd.in/gDPJef-W #JANX #TCellEngagers #cancer #oncology #immunotherapy #immunomodulator #immunooncology #clinicaltrial #mCRPC #prostatecancer

Today we reported our third quarter (Q3) financial results and business highlights. Enrollment is ongoing for PSMA-TRACTr (JANX007) in prostate cancer and EGFR-TRACTr (JANX008) in solid tumors.  An update on JANX007 data and doses selected for expansion cohorts is anticipated by year end. An update on JANX008 data is expected in 2025.   Read the press release for more:  https://lnkd.in/gXvq7s4b   #Q3Earnings #ProstateCancer #cancer #TRACTr #TRACIr #TCellEngagers #JANX

#Movember2024 has arrived, the #JanuxMoBros are proud to participate again! Over the next 30 days, they’ll be growing mustaches to raise awareness for men's health. Learn more about #Movember and #prostatecancer here: https://lnkd.in/gPykynKt  #MensHealthAwareness #ProstateCancerAwareness #GoJanux

Our greatest asset at Janux is our people, and their job satisfaction is one of the best honors we can achieve! Nearly 90% of Janux employees say it is a great place to work, and we are proud to earn a 𝟐𝟎𝟐𝟒 𝐆𝐫𝐞𝐚𝐭 𝐏𝐥𝐚𝐜𝐞 𝐓𝐨 𝐖𝐨𝐫𝐤 𝐂𝐞𝐫𝐭𝐢𝐟𝐢𝐜𝐚𝐭𝐢𝐨𝐧™ by @Great Place To Work US. On #CertificationNationDay, we send our thanks to our team for your passion and drive for bringing innovative new therapies to cancer patients, and for collaborating everyday with integrity, urgency and commitment. Learn more about #TeamJanux: https://lnkd.in/g8WPWNgJ #GPTWcertified #GreatPlaceToWork